{"name": "Presage Biosciences",
 "permalink": "presage-biosciences",
 "crunchbase_url": "http://www.crunchbase.com/company/presage-biosciences",
 "homepage_url": "http://www.presagebio.com/index.html",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2008,
 "founded_month": 11,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": null,
 "email_address": "",
 "phone_number": "",
 "description": "Better cancer drugs",
 "created_at": "Tue Feb 08 06:45:41 UTC 2011",
 "updated_at": "Mon Jun 10 09:11:48 UTC 2013",
 "overview": "\u003Cp\u003EPresage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[136,
       60],
      "assets/images/resized/0012/0951/120951v2-max-150x150.png"],
     [[136,
       60],
      "assets/images/resized/0012/0951/120951v2-max-250x250.png"],
     [[136,
       60],
      "assets/images/resized/0012/0951/120951v2-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Founder and Chair",
    "person":
     {"first_name": "James",
      "last_name": "Olson",
      "permalink": "james-olson",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0025/2294/252294v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0025/2294/252294v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0025/2294/252294v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Chief Executive Officer ",
    "person":
     {"first_name": "James",
      "last_name": "Towne",
      "permalink": "james-towne",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0025/2301/252301v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0025/2301/252301v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0025/2301/252301v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$12M",
 "funding_rounds":
  [{"round_code": "seed",
    "source_url": "http://www.presagebio.com/history.html",
    "source_description": "",
    "raised_amount": null,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 11,
    "funded_day": 1,
    "investments":
     [{"company": null,
       "financial_org": null,
       "person":
        {"first_name": "David",
         "last_name": "Wu",
         "permalink": "david-wu-2",
         "image":
          {"available_sizes":
            [[[150,
               112],
              "assets/images/resized/0011/6787/116787v2-max-150x150.jpg"],
             [[225,
               169],
              "assets/images/resized/0011/6787/116787v2-max-250x250.jpg"],
             [[225,
               169],
              "assets/images/resized/0011/6787/116787v2-max-450x450.jpg"]],
           "attribution": ""}}}]},
   {"round_code": "a",
    "source_url": "http://www.presagebio.com/releases/Presage_PR_06232010.pdf",
    "source_description": "",
    "raised_amount": 4000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 7,
    "funded_day": null,
    "investments":
     []},
   {"round_code": "partial",
    "source_url": "http://www.sec.gov/Archives/edgar/data/1485311/000148531113000001/xslFormDX01/primary_doc.xml",
    "source_description": "SEC",
    "raised_amount": 8000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 3,
    "funded_day": 13,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "530 Fairview Avenue, N., Suite 1000",
    "address2": "",
    "zip_code": "98109",
    "city": "Seattle",
    "state_code": "WA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}